CIRIUM
3.9.2024 11:01:28 CEST | Business Wire | Press release
Cirium is now Condor's new partner for aviation analytics, with the new agreement making Cirium the airline’s single source of external aviation data, providing end-to-end data services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903082962/en/
Condor A330neo (Photo: Business Wire)
The partnership between Cirium, the aviation analytics firm, and Condor, will empower the German carrier to further improve its operations, driving quality insights aimed at improving the businesses efficiency and overall customer satisfaction.
As part of this new agreement, Cirium will provide the airline with three key data sets: historical flight data, schedules data, and real-time flight data.
Having utilised Cirium's historical flight data for two years, Condor's decision to now integrate Cirium’s additional suite of products presents a unique opportunity to further streamline operations, driving direct improvements for both the business and its customers.
This investment in data will enable the business to swiftly identify operational trends, allowing for quick solutions that reduce costs and enhance efficiency. It will empower teams to optimise fleet management, network planning, connections, and crew scheduling, driving significant improvements across all aspects of operations.
Cirium’s highly regarded flight schedules product is also part of the deal, offering deeper insights into service opportunities and market demand. With the up-to-date data, Condor will be able to optimise network and crew planning, boosting efficiency and profitability across the business.
The addition of Cirium’s real-time flight data will also provide live updates on aircraft around the world, meaning flights can be tracked and monitored with greater detail.
This will support Condor’s investment in its customer experience proposition, with Cirium’s live flight data feeding directly into customer-facing digital platforms, giving travellers precise departure and arrival times so they can plan their onward journeys. The addition of real-time flight data will also transform disruption management, offering even faster rebooking options to those with missed connections.
Jeremy Bowen, Cirium CEO, said: “We are very excited to announce this expanded collaboration with Condor, a leading global leisure airline. Condor has been a client of Cirium, benefiting from our historical flight data, and this strengthened partnership is a testament to both the quality of our data and the dedication of the Cirium team. Through this extended relationship, we will provide Condor with the most precise and reliable industry data, helping them enhance operational performance and, most importantly, deliver timely insights to their passengers worldwide.”
As Germany's most popular leisure airline, Condor has been flying customers to the world’s most beautiful destinations since 1956. With a fleet of over 50 aircraft, the airline serves around 90 destinations from Germany and Switzerland. This partnership with Cirium marks the latest step in Condor’s ongoing commitment to operational excellence and customer satisfaction.
Cirium is the world’s most trusted source of aviation analytics, delivering powerful data and cutting-edge analytics to empower a wide spectrum of industry players.
Equipping airlines, airports, travel enterprises, aircraft manufacturers, and financial entities, the company provides the clarity and intelligence needed to optimise operations, make informed decisions and accelerate revenue growth.
To learn more about Cirium’s products, and how they can benefit your business, visit www.cirium.com
About Condor
As Germany's most popular leisure airline, Condor has been taking its guests to the world's most beautiful holiday destinations since 1956. Condor operates a fleet of over 50 aircraft, which are maintained by the company's own maintenance operation, Condor Technik GmbH, according to the highest safety standards at the Frankfurt and Dusseldorf locations. In spring 2022, Germany's most popular leisure airline unveiled its new brand identity. This illustrates the development from a leisure airline to a unique and unmistakable vacation brand. The new design was unveiled with the first A330neo, which has been operated by Condor since December 2022. As the German launch customer, Condor will then be flying 21 A330neo long-haul aircraft. Thanks to state-of-the-art technology and maximum efficiency, the latest-generation 2-liter aircraft is the European front-runner with 2.1 liters per passenger per 100 kilometers and maximum customer comfort. Condor will also receive 43 brand-new short- and medium-haul aircraft of the A32Xneo family from 2024.
About Cirium
Cirium® is the world’s most trusted source of aviation analytics, delivering powerful data and cutting-edge analytics to empower a wide spectrum of industry players. Equipping airlines, airports, travel enterprises, aircraft manufacturers, and financial entities, the company provides the clarity and intelligence needed to optimise operations, make informed decisions and accelerate revenue growth.
Cirium® is part of LexisNexis® Risk Solutions, a RELX business, which provides information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
To learn more about Cirium’s products, and how they can benefit your business, visit www.cirium.com, and follow Cirium on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903082962/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom